FINWIRES · TerminalLIVE
FINWIRES

MannKind Says FDA Approves Afrezza for Children, Adolescents With Diabetes

By

MannKind (MNKD) said Friday the US Food and Drug Administration approved Afrezza, its inhaled mealtime insulin, for use in children and adolescents aged six and older with type 1 or type 2 diabetes.

The approval expands Afrezza's label beyond adults and was supported by results from the phase 3 INHALE-1 study and additional long-term safety and efficacy data, the company said.

MannKind said eligible patients can access Afrezza for $35 or less per month through its patient support program.

Price: $3.80, Change: $+0.16, Percent Change: +4.40%

Related Articles

Wire

Wedbush Adjusts Price Target on Replimune Group to $6 From $2, Maintains Neutral Rating

Replimune Group (REPL) has an average rating of underweight and mean price target of $2.20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $8.38, Change: $+3.70, Percent Change: +78.95%

$REPL
Wire

Neurocrine Biosciences Should See More Upside on Crenessity Growth, RBC Says

Neurocrine Biosciences (NBIX) could see more upside from wider Crenessity use, easing insurance limits, stronger patient demand and likely commercial product beats in 2026, RBC Capital Markets said in a note Friday.RBC said its survey of 35 endocrinologists showed Crenessity still has room to grow after a strong Q1, even as some investors worry near-term demand may slow as surveyed doctors now use Crenessity in about 23% of their Congenital Adrenal Hyperplasia patients on average and expect usage to reach 37% by the end of 2026.The firm raised its 2026 Crenessity sales estimate to $750 million from $734 million, above the roughly $650 million consensus estimate, saying the target looks achievable even with more cautious growth assumptions and longer-term demand also looks strong, with doctors expecting to use Crenessity in just over half of their CAH patients within five years.Insurance approvals remain the main barrier to wider use, but RBC expects those issues to ease over time and support further adoption, according to the note.RBC kept the company's outperform rating and raised its price target to $183 from $180.Price: $157.29, Change: $+0.90, Percent Change: +0.58%

$NBIX
Wire

Okta Continues to Build Momentum After Strong Q1, RBC Says

Okta (OKTA) reported a strong fiscal Q1 with outperformanceacross the board and a guidance raise, RBC Capital Markets said in a Friday note."Momentum is building for both new products and a GTM perspective with specialization and capacity increase benefits both yielding results," the report said.Based on accelerating current remaining performance obligation growth, additional upside to fiscal 2027 estimates seems likely given strong execution and positive demand signals, it said.The note also said early traction with agentic security remains encouraging and could represent a source of upside.RBC maintained its outperform rating and raised its price target to $122 from $108 on higher estimates.Price: $120.31, Change: $+25.59, Percent Change: +27.02%

$OKTA